AccuMed and Shanghai Pharmaceuticals' Concorde Medical Forge Strategic Alliance to Advance Domestic Electrophysiology Ecosystem
AccuPulse
Developer of products in the field of cardiac electrophysiology
Recently,Shanghai Biomedical Fund, under Shangshi Capital, invested in AccuPulse Medical Technology Co., Ltd. (hereinafter referred to as "AccuPulse Medical")Formally signed a strategic partnership framework agreement with SPH KDL HEALTH (SHANGHAI) Logistics Co., Ltd. (hereinafter referred to as "SPH KDL HEALTH").The two parties engaged in in-depth discussions on technological innovation in the electrophysiology industry, opportunities for domestic substitution, and future directions of cooperation. They announced plans to create an efficient and optimized medical supply chain ecosystem through business model innovation, supporting high-quality development in the electrophysiology healthcare sector.
AccuPulse Medical Technology Co.Ltd was led by Shanghai Biomedical Fund in its Pre-A round financing in 2021, with continued investment in the A and A+ rounds.Since its establishment, the company has always focused on platform-based technological innovation in the field of cardiac electrophysiology, striving to serve more patients with atrial fibrillation.
Swipe left or right to view more
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Centering on pulsed field ablation (PFA) and innovative 3D mapping technology, AccuPulse has developed over 10 product pipelines covering the entire process of diagnosis and treatment for arrhythmias such as atrial fibrillation and premature ventricular contractions. It is committed to providing patients with a one-stop solution for atrial fibrillation treatment and assisting doctors and patients in better managing the treatment of atrial fibrillation and other arrhythmia conditions.
As an innovative healthcare and full value chain service enterprise under Shanghai Pharmaceuticals Holding, SPH KDL HEALTH actively builds a medical device distribution platform and full supply chain services, committed to constructing a full value chain service system integrated with distinctive value-added capabilities. At the same time, relying on Shanghai Pharmaceuticals Holding's nationwide distribution network and highly efficient third-party logistics services in China, SPH KDL HEALTH can provide full-chain support for medical innovation products from production, clinical trials to commercialization, ensuring rapid and precise delivery of products to end users.
Xu Keda
Deputy General Manager of Shanghai Pharmaceuticals Holding, General Manager of SPH KDL HEALTH
Xu Keda, Deputy General Manager of Shanghai Pharmaceutical Holdings and General Manager of SPH KDL HEALTH (SHANGHAI) Logistics Co., Ltd.Highlight: Achieving the leap from laboratory to operating room in just four years, AccuPulse has redefined the industrialization speed of innovative devices. Behind this breakthrough achievement lies the triple resonance of AccuPulse's team: "technical problem-solving ability, clinical transformation ability, and resource integration capability." The powerful collaboration between AccuPulse's technical breakthroughs and SPH KDL HEALTH (SHANGHAI) Logistics Co., Ltd. is essentially a multiplication of "innovation density" and "channel breadth."
Yin Jie
CEO of AccuPulse Medical
AccuPulse CEO Yin JieSpeech: The cooperation between AccuPulse and SPH KDL HEALTH (SHANGHAI) Logistics Co., Ltd. brings together "favorable timing, geographical advantages, and harmonious people": policy benefits, market boom, and accelerated innovation in medical devices lay the foundation for cooperation; complementary resources and core strengths empower both parties; and through localized innovation and business model upgrades with "dual-track synergy," they achieve "harmonious people."
Zhang Qiyu
Director of Investment, Shanghai Biomedical Fund
Zhang Qiyu, Investment Director of Shanghai Biomedical FundSpeech: From the faint glimmer of laboratory research to the current product launch, the AccuPulse team has achieved an astonishing leap from scientific concept to clinical value in just four years. This powerful collaboration with SPH KDL HEALTH (SHANGHAI) Logistics Co., Ltd. will also create a new paradigm in the advancement of China's high-end medical device industry.
This collaboration represents the integration of resources between two enterprises, establishing a "proprietary technology + super channel" platform-based cooperation model. Through innovative cooperation in a platform-based model, AccuPulse Medical and SPH KDL HEALTH (SHANGHAI) Logistics Co., Ltd. are expected to provide replicable experiences for the industry, promoting the overall efficiency enhancement of the medical industry chain.